[{"address1": "2430 North Halsted Street", "city": "Chicago", "state": "IL", "zip": "60614", "country": "United States", "phone": "847 673 1700", "fax": "847 556 6411", "website": "https://www.exicuretx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.", "fullTimeEmployees": 7, "companyOfficers": [{"maxAge": 1, "name": "Mr. Paul  Kang", "age": 61, "title": "CEO & Director", "yearBorn": 1962, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jiyoung  Hwang", "age": 46, "title": "CFO & Director", "yearBorn": 1977, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua  Miller", "age": 47, "title": "Chief Accounting Officer", "yearBorn": 1976, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bart  Anderson", "title": "Senior Director of R&D", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 10, "governanceEpochDate": 1709251200, "maxAge": 86400, "priceHint": 4, "previousClose": 0.7194, "open": 0.653, "dayLow": 0.65, "dayHigh": 0.7128, "regularMarketPreviousClose": 0.7194, "regularMarketOpen": 0.653, "regularMarketDayLow": 0.65, "regularMarketDayHigh": 0.7128, "beta": 1.27, "trailingPE": 0.36723164, "forwardPE": -0.84415585, "volume": 49531, "regularMarketVolume": 49531, "averageVolume": 1003645, "averageVolume10days": 61410, "averageDailyVolume10Day": 61410, "bid": 0.6477, "ask": 0.7, "bidSize": 900, "askSize": 1100, "marketCap": 5621401, "fiftyTwoWeekLow": 0.365, "fiftyTwoWeekHigh": 1.5, "priceToSalesTrailing12Months": 0.2362926, "fiftyDayAverage": 0.61904, "twoHundredDayAverage": 0.77311, "currency": "USD", "enterpriseValue": 10380531, "profitMargins": 0.12884, "floatShares": 7807259, "sharesOutstanding": 8648310, "sharesShort": 219106, "sharesShortPriorMonth": 821091, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0253, "heldPercentInsiders": 0.45039, "heldPercentInstitutions": 0.09804, "shortRatio": 0.4, "shortPercentOfFloat": 0.029000001, "impliedSharesOutstanding": 8648310, "bookValue": 1.122, "priceToBook": 0.57932264, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1688083200, "netIncomeToCommon": 3065000, "trailingEps": 1.77, "forwardEps": -0.77, "lastSplitFactor": "1:30", "lastSplitDate": 1656547200, "enterpriseToRevenue": 0.436, "enterpriseToEbitda": 2.438, "52WeekChange": -0.41192168, "SandP52WeekChange": 0.30279303, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "XCUR", "underlyingSymbol": "XCUR", "shortName": "Exicure, Inc.", "longName": "Exicure, Inc.", "firstTradeDateEpochUtc": 1526995800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "ee4bcb27-f318-38c7-8572-459785e7d845", "messageBoardId": "finmb_82271676", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.65, "recommendationMean": 3.0, "recommendationKey": "hold", "totalCash": 2335000, "totalCashPerShare": 0.27, "ebitda": 4257000, "totalDebt": 6999000, "quickRatio": 1.632, "currentRatio": 2.56, "totalRevenue": 23790000, "debtToEquity": 72.117, "revenuePerShare": 3.857, "returnOnAssets": 0.07356, "returnOnEquity": 0.56404, "freeCashflow": -11545000, "operatingCashflow": -21953000, "grossMargins": 0.17617, "ebitdaMargins": 0.17894, "operatingMargins": 0.13485, "financialCurrency": "USD", "trailingPegRatio": null}]